TargetRx

TargetRx (Shenzhen TargetRx, Inc.) is a clinical-stage biopharmaceutical company focused on developing the next generation of targeted cancer therapies. Founded in August 2014, this Sino-US joint venture is headquartered in Shenzhen, China. The company directs its efforts toward creating small molecule drugs designed to overcome acquired resistance to existing cancer treatments, a significant challenge in oncology.

The company was founded by Dr. Yihan Wang, who also serves as Chairman and CEO. Dr. Wang is a distinguished medicinal chemist with over 16 years of experience in the United States, primarily at Ariad Pharmaceuticals. There, he was a core inventor of several internationally recognized first-in-class drugs, including Iclusig® (Ponatinib) and Alunbrig® (Brigatinib). Motivated by the realization that many Chinese patients could not access advanced cancer medications, Dr. Wang returned to China, leveraging his expertise to establish TargetRx with the mission of developing affordable, superior drugs for the local and global markets. The company has successfully raised significant capital through multiple funding rounds, including a Series C in January 2025 for $50 million, to advance its clinical programs.

TargetRx's business model centers on the in-house research, development, and eventual commercialization of proprietary small molecule inhibitors. The company's revenue strategy appears to be based on future drug sales and strategic partnerships, actively seeking global collaborators for out-licensing and co-development to maximize the value of its assets. The company's primary clients are patients with specific forms of cancer, such as chronic myeloid leukemia (CML) and non-small cell lung cancer (NSCLC), who have developed resistance to prior therapies.

The company's product pipeline features several drug candidates with best-in-class potential. Key assets include TGRX-678, a fourth-generation BCR-ABL inhibitor for CML, and TGRX-326, a dual ALK/ROS1 inhibitor for NSCLC. These compounds are engineered with unique structural features to be effective against mutations that cause resistance to earlier-generation drugs and to exhibit improved safety profiles. TGRX-326 is also designed to cross the blood-brain barrier, addressing the critical issue of brain metastases in lung cancer patients. TargetRx has built a robust R&D platform covering drug design, synthesis, and biological evaluation, backed by an intellectual property portfolio of over 170 patents worldwide.

Keywords: targeted therapy, oncology, drug resistance, small molecule drugs, chronic myeloid leukemia, non-small cell lung cancer, pharmaceutical R&D, Yihan Wang, BCR-ABL inhibitor, ALK/ROS1 inhibitor, clinical-stage, biopharmaceutical, cancer treatment, TGRX-678, TGRX-326, Ponatinib, Brigatinib, drug discovery, precision medicine, molecularly targeted drugs